Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBT (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed EBT for 10 consecutive years, with -$11.2 million as the latest value for Q4 2025.

  • Quarterly EBT rose 50.73% to -$11.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.7 million through Dec 2025, up 94.64% year-over-year, with the annual reading at -$3.7 million for FY2025, 94.64% up from the prior year.
  • EBT for Q4 2025 was -$11.2 million at Akebia Therapeutics, down from $1.2 million in the prior quarter.
  • The five-year high for EBT was $29.0 million in Q2 2022, with the low at -$84.3 million in Q2 2021.
  • Average EBT over 5 years is -$25.3 million, with a median of -$16.2 million recorded in 2023.
  • The sharpest move saw EBT soared 134.44% in 2022, then crashed 3814.01% in 2024.
  • Over 5 years, EBT stood at -$70.4 million in 2021, then surged by 90.76% to -$6.5 million in 2022, then soared by 109.44% to $614000.0 in 2023, then plummeted by 3814.01% to -$22.8 million in 2024, then skyrocketed by 50.73% to -$11.2 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$11.2 million, $1.2 million, and $247000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.